MSB Trading 2021 - paradigm shift, page-7619

OMG … what a puff piece.

Our old friends at Bell “bullish” Potter as reported in the Fool. But even then they are again trimming their sp expectations down to $3.45. Wasn’t it $3.70 only a little while ago?

Maybe their way of pricing this stock is to downgrade their prediction to match double the current sp?

Anyway, even if you accept their 12 month prediction of $3.45 is correct, it’s hard to see what will have occurred between then and now. Certainly not an approval from the FDA which should see a SP of over $5. So, no approval within 12 months. Which is what everyone who is objective would expect given trials need to occur first.

I’d say the SP prediction would be on an expectation a trial result might be delivered late 2022, early 2023. There would be the usual MSB optimism building up again by then.